Ars Pharmaceuticals is expanding its $199 neffy retail access program while awaiting a crucial decision from CVS Caremark, aiming to boost affordability...
LENZ Therapeutics delivered Q1 2026 results consistent with expectations, achieving $1.9 million in net revenue and approximately 25,000 prescriptions. The company also...
NeoGenomics forecasts significant revenue growth for 2026, projecting between $797 million and $803 million, boosted by the PanTracer Liquid MolDX approval.
Beyond its weight-loss drug success, Eli Lilly's robust pipeline across oncology, immunology, and neuroscience presents a compelling investment thesis.
Enveric Biosciences announced a private placement expected to raise up to $13.9 million, with $5 million upfront and potential additional proceeds from...